hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion

Jun Jiao¹,² | Teng Zhang¹,² | Xinlin Jiao¹,² | Tingting Huang²,³ | Lu Zhao¹,² | Daoxin Ma² | Baoxia Cui¹

¹Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China
²Hematology Oncology Center, Qilu Hospital of Shandong University, Jinan, China
³Department of Obstetrics and Gynecology, Taian City Central Hospital, Taian, China

Abstract
Circular RNAs (circRNAs) participate in gene regulation and malignant tumor progression, including uterine cervical cancer (CC). In this study, the expression profile of circRNAs in CC was detected using circRNA microarrays. Then, we selected hsa_circ_0000745 for further examination from the significantly dysregulated circRNAs. Proliferation assays, Transwell assays, quantitative reverse transcription polymerase chain reaction, western blot analysis and tumorigenesis tests in vivo were used to validate the role of hsa_circ_0000745 in CC. hsa_circ_0000745 was upregulated in CC, and its level positively correlated with the level of its linear messenger RNA isoform. Patients with poorly differentiated tumors or vascular/lymphatic invasion presented higher expression of hsa_circ_0000745. The role of hsa_circ_0000745 was illuminated by knocking down hsa_circ_0000745 in CC cells, and the results revealed that reducing hsa_circ_0000745 inhibited cell proliferation, migration, and invasion in CC by upregulating E-cadherin (E-cad) expression. In summary, as a tumor promoter in CC, hsa_circ_0000745 enhances the cell’s ability to proliferate, migrate, and invade by reducing the expression of E-cad. hsa_circ_0000745 is a candidate target for the treatment of CC in the clinic.

KEYWORDS
cervical cancer, circular RNA, E-cadherin, hsa_circ_0000745, squamous cell carcinoma

1 | INTRODUCTION

Uterine cervical cancer (CC) ranks as the 3rd most common cancer and the 4th most common cause of cancer-related death in women worldwide (Ferlay et al., 2015). Approximately 80% of CC cases are squamous cell carcinoma (SCC). Persistent infection with high-risk human papillomavirus (HPV) is a primary factor but not a necessary condition that causes CC (Munoz, Castellsague, de Gonzalez, & Gissmann, 2006). HPV vaccination and early detection programs can reduce the morbidity of CC; however, the effect of these regimens is limited worldwide. Many countries with inadequate healthcare systems suffer from higher CC morbidity and mortality rates. Although its incidence ranks only 11th in developed countries, the incidence of CC ranks second in developing areas (Ginsburg et al., 2017). The mechanisms underlying the occurrence and development of CC must be elucidated to reduce the morbidity and mortality of CC in addition to high-risk HPV infections.

Circular RNA (circRNA) belongs to noncoding RNA (ncRNA) that participates in regulating gene expression and tumor progression (Meng et al., 2017; Wang, Nazarali, & Ji, 2016). The joining of 3’ end
and 5’ end of the RNA creates the circular shape of the circRNAs (Suzuki & Tsukahara, 2014). There are several mechanisms by which circRNAs participate in cellular biology. circRNAs contain multiple binding sites for microRNAs (miRNAs). circRNAs bind miRNAs at their miRNA response elements to inhibit the activities of the miRNAs and regulate their targets (Cai et al., 2019; Han et al., 2017; Hansen, Jensen, et al., 2013). Research on this role is a hotspot of circRNA research. circRNAs directly regulate the transcription of linear RNAs through competitive splicing and regulate the expression of proteins by isolating RNA-binding proteins that normally make up RNA-protein complexes to control the expression of genes (Li et al., 2015; Wilusz & Sharp, 2013).

The abnormal expression of circRNAs is closely related to various cancers. circZKSCAN1, which may be a useful diagnostic marker, suppresses the growth and metastasis of hepatocellular carcinoma (Yao et al., 2017). circPSMC3 inhibits the development and metastasis of gastric cancer (GC) by inhibiting functions of miR-296-5p (Rong et al., 2019). Aberrantly expressed circRNAs have also been identified in CC. The expression profiles of ncRNAs, including circRNA, have been explored in CC using high-throughput RNA sequencing, and circRNAs represent potentially new diagnostic and therapeutic markers of CC (Wang, Zhao, Chen, & Cui, 2017). circ_0067934 participates in CC development by regulating miR-545 expression and promotes the progression of CC (Hu et al., 2019). A previous study (Yu et al., 2018) identified circRNAs that are dysregulated in the response to radiation in CC cells using high-throughput sequencing. Based on the results, these circRNAs may function in the response of CC to radiation in humans. But the specific role of circRNAs in CC still remains largely unknown.

In this study, a circRNA microarray analysis was conducted to detect the aberrantly expressed circRNAs in CC tissues. hsa_circ_0000745 (hereafter referred to as circ_00745) was selected for in-depth study among the dysregulated circRNAs because of its significantly abnormal expression according to the microarray result. circ_00745 is transcribed from the sperm antigen with calponin homology and coiled-coil domains 1 (SPECC1) located on chromosome 17. circ_00745 expression was markedly upregulated in CC. Functionally, downregulation of circ_00745 obviously suppressed the proliferation, migration, and invasion of CC cells. According to our findings, circ_00745 promoted CC cell proliferation and metastasis; therefore, circ_00745 represents a potential prognostic and therapeutic marker for CC patients.

**TABLE 1** Clinical and histopathological characteristics of SCC patients for circRNA microarray analysis

| Patient ID | Age | Clinical stage | Differentiation | Tumor size (cm) | Lymphnode metastases | Vascular/lymphatic invasion |
|------------|-----|----------------|-----------------|-----------------|---------------------|--------------------------|
| 1          | 32  | IB2            | Moderate        | ≥4              | Negative            | Positive                 |
| 2          | 32  | IB1            | Low             | <4              | Negative            | Negative                 |
| 3          | 41  | IB1            | Low             | <4              | Negative            | Negative                 |
| 4          | 44  | IIA            | Low             | <4              | Negative            | Negative                 |
| 5          | 41  | IB1            | High            | <4              | Negative            | Negative                 |

Abbreviation: circRNA, circular RNA; SCC, squamous cell carcinoma.
TABLE 2 The sequences of primers for qRT-PCR and siRNAs

| RNA                          | Sequence                                      |
|------------------------------|-----------------------------------------------|
| hsa_GAPDH forward sequence   | 5'-GGGAAACTGTCGGCGTGAT-3'                     |
| hsa_GAPDH reverse sequence   | 5'-GAGTGCGGTGCGCGTCTGA-3'                     |
| hsa_circ_0000745 forward    | 5'-ATGTTGAAATGAGCCCGAGACG-3'                  |
| sequence                    |                                               |
| hsa_circ_0000745 reverse    | 5'-TGAGGTGTTGGAAGAAGTGG-3'                    |
| sequence                    |                                               |
| Linear SPECC1 mRNA forward  | 5'-ACCCCAAGAAATCGATGTCCA-3'                   |
| reverse sequence            |                                               |
| Linear SPECC1 mRNA reverse  | 5'-GTTCGGAACCTGGACTCAA-3'                     |
| sequence                    |                                               |
| siRNA-1                     | 5'-CTGGCCAAGGGGCCUCUACTT-3'                   |
| sequence                    |                                               |
| siRNA-2                     | 5'-CUUGGCAAGGGGCCUUACATT-3'                   |
| sequence                    |                                               |
| siRNA-3                     | 5'-GUCCGCGCGCAAGGCCCCTT-3'                    |
| sequence                    |                                               |
| si-Negative control         | 5'-UUCUUGCAAGCCGUGUCAGUTT-3'                  |

Note: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; qRT-PCR, quantitative reverse transcription polymerase chain reaction; siRNA, small interfering RNA.

PCR mixture contained 2 μl of the complementary DNA templates, a 1 × final concentration of SYBR Green (Toyobo, Osaka, Japan), and the specific primers. The sequences of the primers synthesized by Biosune (Shanghai, China) are shown in Table 2. All tests were conducted in triplicate on a LightCycler 480 II (Roche, Basel, Switzerland). Relative expressions of circ-0745 and linear SPECC1 mRNA were calculated with 2^−ΔΔCt method.

2.7 | Cell migration and invasion assay

Transwell chambers (Corning) without and with a basement membrane coating (Corning) were used to detect the mobility of transfected CC cells, respectively. For migration test, 2.5 × 10^4 cells were placed into chambers of Transwell inserts without basement membrane coating; for the invasion test, 5 × 10^4 cells were seeded in chambers of Transwell inserts with a basement membrane coating. After 24 hr, nonmigratory or noninvasive cells were wiped and the cells migrating through the membrane were counted under a microscope (Olympus, Tokyo, Japan).

2.8 | Subcutaneous tumor formation in mice

The sequence of siRNA-2 was inserted a lentiviral vector for the stable knocked down of circ-0745 (named sh-circ-0000745). sh-circ-0000745 and an empty lentiviral vector as nonsense control (Genechem Co., Shanghai, China) were constructed containing the green fluorescent protein gene and a puromycin resistance gene. CaSkii cells were transfected and selected with puromycin (2 μg/ml; Sigma) to obtain stable cell clones.

All animal care and experimental procedures were conducted according to the standards of the National Institutes of Health and approved by the Animal Protection and Use Committee of Shandong University. First, 10^7 stably transfected CaSkii cells were subcutaneously injected into the backs of female BALB/c mice (5 weeks old). The tumors were monitored weekly. The mice were killed after 4 weeks, and tumors were excised and assessed.

2.9 | Western blot analysis

After transfected for 48 hr, CaSkii and SiHa cells were lysed with radioimmunoprecipitation assay buffer (Sigma). Proteins were extracted and electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gels, then transferred to nitrocellulose filter membranes. The membranes were incubated overnight with a primary E-cadherin antibody (E-cad, 1:1000; Cell Signaling Technology, Boston) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:1000; Cell Signaling Technology). Then a horseradish peroxidase-conjugated secondary antibody (1:1000; Cell Signaling Technology) was used. Protein bands were visualized using a FluoroChem E system (Protein Simple, Silicon Valley) and the signals were quantified. GAPDH was measured as a loading control.

2.10 | Statistical analyses

Data are presented as the means ± SD. Comparisons between two groups were performed using Student's t test. Correlation analysis was performed with Pearson’s analysis. Differences were considered significant at p < .05. All statistical analyses were performed with SPSS 18.0.
3 | RESULTS

3.1 | Differentially expressed circRNAs in SCC

Overall, 3,008 human circRNAs were detected in SCC tissue and normal cervical tissue cells. One hundred seventy-eight circRNAs exhibited abnormal expression in SCC samples (fold change > 2.0), indicating their dysregulation. Volcano plot filtering showed the expression patterns of circRNA among the samples (Figure 1a).

Further analysis found that there were 77 upregulated and 101 downregulated circRNAs in SCC tissues compared with the levels in the paired control group. Classification of the 77 upregulated circRNAs revealed 68 exonic, 3 intronic, 1 antisense, and 5 intragenic circRNAs (Figure 1b), the 101 downregulated circRNAs included 81 exonic, 13 intronic, 3 antisense, and 4 intragenic circRNAs (Figure 1b). Several circRNAs showed approximately 10-fold changes in their expression between the normal and cancerous cervical tissues. Twenty-four differentially expressed circRNAs are shown in Figure 1c. The microarray data has been uploaded to the NCBI Gene Expression Omnibus (GEO) website (GSE102686).

3.2 | circ-0745 is upregulated in SCC

In the circRNA microarray, circ-0745 was detected in cervical cells using a probe specific for the junction site of circ-0745. circ-0745 displayed significant differences in expression between SCC and normal cervical cells (Figure 1c). We detected the levels of both circ-0745 and the linear SPECC1 mRNA in 59 paired SCC and paracancerous cervical tissues using qRT-PCR. Compared with the control tissues, circ-0745 was upregulated in SCC (p < .001; Figure 2a), consistent with the result from the circRNA microarray. The linear SPECC1 mRNA was also upregulated in the SCC group (p < .001; Figure 2b). Furthermore, circ-0745 positively correlated with the expression of the linear SPECC1 mRNA in SCC tissues (r = 0.449, p < .001; Figure 2c). Interestingly, a higher circ-0745/linear SPECC1 mRNA ratio was observed in SCC tissues than in the control (p < .001; Figure 2d). Based on these findings, circ-0745 was involved in the development of SCC.

3.3 | circ-0745 is related to patients’ clinicopathological parameters

The relationships between the levels of circ-0745 and several clinicopathological characteristics (Table 3) that may affect the treatment and prognosis of patients with CC were analyzed. Compared with patients with SCC presenting with well or moderately differentiated tumors, patients with poorly differentiated tumors exhibited substantially increased circ-0745 expression (p = .005; Figure 2e). Patients with positive vascular/lymphatic invasion exhibited higher levels of circ-0745 than patients without vascular/lymphatic invasion (p = .026; Figure 2f). No significant correlation was detected between circ-0745 expression and other prognostic factors in patients with SCC, including the clinical stage, tumor size, and lymph node metastasis. Poor differentiation and positive vascular/lymphatic invasion often indicate an unfavorable prognosis and follow-up treatment with chemoradiotherapy. The observed associations suggested that patients with SCC presenting with higher levels of circ-0745 may have a worse prognosis than patients with lower levels of circ-0745.

In this study, we collected specimens from only CC patients with Stage I and II because patients with more advanced stages were treated with radiotherapy or chemotherapy rather than with...
surgery. Because we were unable to collect a sufficient number of cancer tissues from individuals with Stage III or Stage IV disease, the analysis between circ_0745 expression and the patients’ clinical stages was restricted to early stages.

### 3.4 Inhibition of circ-0745 suppresses CC cell proliferation

In SiHa and CaSki cells, specifically designed siRNAs were used to knockdown circ-0745 expression. circ-0745 expression was significantly reduced in cells transfected with siRNA-2; this construct was used in all subsequent analyses (Figure 3a). Compared with the negative-control treatment, circ-0745 knockdown obviously suppressed the proliferation ability of SiHa and CaSki cells, as examined using CCK-8 assays (Figure 3b,c). Flow cytometry was conducted to detect cell apoptosis after circ-0745 expression was silenced. Changes in the expression of circ-0745 had no effect on the apoptosis of SiHa or CaSki cells (p > .05).

The role of circ-0745 in promoting CC cell proliferation was tested by generating a subcutaneous tumor model in nude mice. Tumor volume = Length × Width × Height × π/6. The volume of neoplasms in the sh-circ_0000745 group was markedly smaller than in the control (p < .05; Figure 3d), which indicated that inhibiting hsa_circ_0000745 obviously suppressed CC cells’ proliferation in vivo.

### 3.5 Inhibition of circ-0745 inhibits CC cells migration and invasion by upregulating E-CAD

SiHa and CaSki cells showed decreased migration through a Transwell chamber after downregulation of circ-0745 (p < .001; Figure 4a), there was a similar trend detected in the invasion experiments (p < .01; Figure 4b). Based on these results, knockdown of circ-0745 noticeably inhibited the migratory and invasive ability of
SiHa and CaSki cells. We also measured the relationship between circ-0745 and E-cad expression. After downregulating the expression of circ-0745, the levels of E-cad were increased in both SiHa and CaSki cells (p_{SiHa} < .01 and p_{CaSki} < .001; Figure 4c), suggesting that the downregulation of circ-0745 induced E-cad expression to suppress CC cells migration and invasion.

4 | DISCUSSION

Although previously neglected as byproducts, circRNAs first attracted attention after the identification of ciRS-7, a circRNA also known as CDR1as. ciRS-7, a designated sponge and inhibitor of miR-7, conceptually changed the understanding of the mechanisms of miRNAs and gene regulation networks (Hansen, Jensen, et al., 2013; Hansen, Kjems, & Damgaard, 2013). Due to the wide use of high-throughput sequencing and microarray assays, increasing numbers of circRNAs have been identified in human samples. Currently, because of ongoing research and the publication of new information about circRNA biogenesis, regulation, and expression patterns, functions of circRNAs in addition to their miRNA-sponge activities have been identified, including as competitors with linear mRNAs (Ashwal-Fluss et al., 2014), protein decoys (Abdelmohsen et al., 2017; Du et al., 2017), and protein translation (Liang et al., 2019; Yang et al., 2017). Notably, circRNAs have attracted increasing attention from cancer researchers (Bach, Lee, & Sood, 2019; Hsiao et al., 2017; Zhang & Xin, 2018). Understanding the roles of circRNAs will provide new insights into oncogenesis and tumor development, thereby providing a foundation for novel cancer detection and treatment methods. Here, we identified differentially expressed circRNAs in tumor tissues from CC patients compared with matched adjacent cervical tissues. One hundred seventy-eight aberrantly expressed circRNAs were detected and subjected to a preliminary analysis. As differentially expressed...
circRNAs have different functions in carcinoma genesis and progression, the specific roles of dysregulated circRNAs must be studied. We further investigated one differentially expressed circRNA, circ-0745, and identified an important role for this circRNA in CC development. circ-0745 is derived from the gene SPECC1. After transcription, the pre-mRNA of SPECC1 is spliced into the linear SPECC1 mRNA and the circRNA isoform, circ-0745. The linear isoform functions in cancer development, participating in cell proliferation and apoptosis (D’Agostino & Giordano, 2008); the function of circ-0745 in the development of malignant tumors attracted our interest. circ-0745 is reduced in GC patients’ tumor tissues and blood plasma. In addition, circ-0745 correlates with the tumor-node-metastasis stage, revealing circ-0745 plays a pivotal role and is a promising marker in GC (Huang, He, Liang, Huang, & Zhu, 2017). In our study, circ-0745 is aberrantly upregulated in CC tissues, according to both circRNA microarray and qRT-PCR results. These results suggest the same circRNA may be differentially expressed in different tissues or organs and play different roles in different diseases.

Correlation analysis between circ-0745 expression and the clinical features of CC patients showed that patients with poor differentiation or positive vascular/lymphatic invasion exhibited much higher levels of circ-0745 than patients with well or moderately differentiated tumors or no vascular/lymphatic invasion. Patients with poor tumor differentiation and/or positive vascular/lymphatic invasion have a worse prognosis and often need post-operative radiotherapy or chemotherapy to reduce the risk of recurrence. Thus, circ-0745 is important in the progression of CC and may influence the prognosis of patients with CC.

Some circRNAs work as tumor suppressors or oncogenes in different types of malignant tumors. For example, circRNA-0000284 is an oncogene and promotes the progression of CC via the miR-506/ Snail-2 pathway (Ma, Yao, Yu, Chen, & Li, 2018), whereas circ-ITCH is a tumor suppressor by suppressing the activity of miR-17/miR-224 and upregulating their target genes in bladder carcinoma (Yang et al., 2018). We downregulated circ-0745 in cancer cells to investigate its function in CC. The CC cells with a low level of circ-0745 exhibited reduced proliferation in vitro and in vivo and reduced invasion and migration in vitro. Thus, circ-0745 functions as an oncogene by
enhancing the malignancy of CC cells, consistent with the finding that patients with poor tumor differentiation or positive vascular/lymphatic invasion presented much higher expression of circ-0745 than patients with well or moderately differentiated tumors and no invasion. Based on these findings, the inhibition of circ-0745 represents a direction for exploring new therapies for CC.

In epithelial cells, E-cad is essential for maintaining the homeostasis of the polarized epithelial monolayer. Downregulation of E-cad is common in tumors manifesting from epithelial tissues and promotes cell migration and invasion (Peng et al., 2018; Sarrio et al., 2004). The downregulation of E-cad during cancer progression is generally considered the result of the epithelial-to-mesenchymal transition (EMT). Reduced E-cad expression during EMT is often considered to be a major driver of cancer progression and metastasis (Kourtidis, Lu, Pence, & Anastasiadis, 2017).

As metastasis is considered the primary cause of death in tumor patients, the mechanism by which circ-0745 promotes CC cell metastasis is worth exploring. Inhibition of circ-0745 elevated the expression of E-cad in CC cells, resulting in the suppression of cell invasion and migration. Based on these results, increased circ-0745 expression inhibits E-cad expression in CC cells, subsequently promoting the metastasis of CC cells and resulting in cancer progression.

In summary, we highlight the expression of circRNAs in human CC. circ-0745 is confirmed to be overexpressed in CC and may be related to the prognosis of patients with CC. Functionally and mechanistically, circ-0745 promotes the cellular ability to proliferate, migrate and invade by reducing the expression of E-cad, indicating its role as a tumor promoter in CC progression. Based on our data, circ-0745 plays an important part in promoting CC development and represents a candidate marker of patient prognosis and a target for clinical treatments for CC.

ACKNOWLEDGMENTS
We sincerely thank all the participants in the study. The study was supported by the National Key R&D Program of China (Grant/Award Number: 2016YFC1302900), Key Research and Development Program of Shandong Province (Grant/Award Number: 2015GSF118097), and Fundamental Research Fund of Shandong University (Grant/Award Number: 2014QLKY23).

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
J.J. performed the experiments and wrote the manuscript. T.Z. and X.J. participated in the experimental work and collection of data. T.H. and L.Z. analyzed the data. D.M. participated in the design and coordination of experimental work. B.C. designed the research, provided reagents and revised the paper. All authors read and approved the final manuscript.

DATA ACCESSIBILITY
The circRNA microarray data of this study are openly available in the NCBI Gene Expression Omnibus (GEO) DataSets (https://www.ncbi.nlm.nih.gov/geo/), accession number GSE102686.

ORCID
Baoxia Cui http://orcid.org/0000-0001-9088-1240

REFERENCES
Abdelmohsen, K., Panda, A. C., Munk, R., Grammatikakis, I., Dudekula, D. B., De, S., & Gorospe, M. (2017). Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by circPABPN1. RNA Biology, 14(3), 361–369.
Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R., Ivanov, A., Bartok, O., Hanan, M., & Kadener, S. (2014). circRNA biogenesis competes with pre-mRNA splicing. Molecular Cell, 56(1), 55–66.
Bach, D. H., Lee, S. K., & Sood, A. K. (2019). Circular RNAs in cancer. Molecular Therapy, Nucleic Acids, 16, 118–129.
Cai, X., Zhao, Z., Dong, J., Lv, Q., Yun, B., Liu, J., & Li, J. (2019). Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. Cell Death & Disease, 10(3), 184.
D’Agostino, L. & Giordano, A. (2008). Possible functional role of NSP5 in cancer. Cell Cycle, 7(12), 1810–1827.
Du, W. W., Yang, W., Chen, Y., Wu, Z. K., Foster, F. S., Yang, Z., & Yang, B. B. (2017). Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. European Heart Journal, 38(18), 1402–1412.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386.
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., & Conteh, L. (2017). The global burden of women’s cancers: A grand challenge in global health. Lancet, 389(10071), 847–860.
Han, D., Li, J., Wang, H., Su, X., Hou, J., Gu, Y., & Cao, X. (2017). Circular RNA circMT01 acts as the sponge ofmicroRNA-9 to suppress hepatocellular carcinoma progression. Hepatology, 64(4), 1151–1164.
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finski, B., Damgaard, C. K., & Kjems, J. (2013). Natural RNA circles function as efficient microRNA sponges. Nature, 495(7441), 384–388.
Hansen, T. B., Kjems, J., & Damgaard, C. K. (2013). Circular RNA andmiR-7 in cancer. Cancer Research, 73(18), 5609–5612.
Hsiao, K. Y., Lin, Y. C., Gupta, S. K., Chang, N., Yen, L., Sun, H. S., & Tsai, S. J. (2017). Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. Cancer Research, 77(9), 2339–2350.
Hu, C., Wang, Y., Li, A., Zhang, J., Xue, F., & Zhu, L. (2019). Overexpressed circ_0067934 acts as an oncogene to facilitate cervical cancer progression via the miR-545/EIF3C axis. Journal of Cellular Physiology, 234(6), 9225–9232.
Huang, M., He, Y. R., Liang, L. C., Huang, Q., & Zhu, Z. Q. (2017). Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer. World Journal of Gastroenterology, 23(34), 6330–6338.
Kourtidis, A., Lu, R., Pence, L. J., & Anastasiadis, P. Z. (2017). A central role for cadherin signaling in cancer. Experimental Cell Research, 358(1), 78–85.
Li, J. Q., Yang, J., Zhou, P., Le, Y. P., Zhou, C. W., Wang, S. M., & Gong, Z. H. (2015). Circular RNAs in cancer: Novel insights into origins, properties, functions and implications. American Journal of Cancer Research, 5(2), 472–480.
Liang, W.-C., Wong, C.-W., Liang, P.-P., Shi, M., Cao, Y., Rao, S.-T., & Zhang, J.-F. (2019). Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biology, 20(1), 84.

Ma, H. B., Yao, Y. N., Yu, J. J., Chen, X. X., & Li, H. F. (2018). Extensive profiling of circular RNAs and the potential regulatory role of circRNA-000284 in cell proliferation and invasion of cervical cancer via sponging miR-506. American Journal of Translational Research, 10(2), 592–604.

Meng, X., Li, X., Zhang, P., Wang, J., Zhou, Y., & Chen, M. (2017). Circular RNA: An emerging key player in RNA world. Briefings in Bioinformatics, 18(4), 547–557.

Munoz, N., Castellsague, X., de Gonzalez, A. B., & Gissmann, L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24(Suppl. 3), S3/1–S3/10.

Peng, S. Y., Tu, H. F., Yang, C. C., Wu, C. H., Liu, C. J., Chang, K. W., & Lin, S. C. (2018). miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression. International Journal of Cancer, 143(11), 2892–2904.

Rong, D., Lu, C., Zhang, B., Fu, K., Zhao, S., Tang, W., & Cao, H. (2019). CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p. Molecular Cancer, 18(1), 25.

Sarrio, D., Perez-Mies, B., Hardisson, D., Moreno-Bueno, G., Suarez, A., Cano, A., & Palacios, J. (2004). Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 23(19), 3272–3283.

Suzuki, H., & Tsukahara, T. (2014). A view of pre-mRNA splicing from RNase R resistant RNAs. International Journal of Molecular Sciences, 15(6), 9331–9342.

Wang, F., Nazarali, A. J., & Ji, S. (2016). Circular RNAs as potential biomarkers for cancer diagnosis and therapy. American Journal of Cancer Research, 6(6), 1167–1176.

Wang, H., Zhao, Y., Chen, M., & Cui, J. (2017). Identification of novel long non-coding and circular RNAs in human papillomavirus-mediated cervical cancer. Frontiers in Microbiology, 8, 1720.

Wilusz, J. E., & Sharp, P. A. (2013). Molecular biology. A circuitous route to noncoding RNA. Science, 340(6131), 440–441.

Yang, C., Yuan, W., Yang, X., Li, P., Wang, J., Han, J., & Zhang, W. (2018). Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Molecular Cancer, 17(1), 19.

Yang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., & Wang, Z. (2017). Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Research, 27(5), 626–641.

Yao, Z., Luo, J., Hu, K., Lin, J., Huang, H., Wang, Q., & Yang, Y. (2017). ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Molecular Oncology, 11(4), 422–437.

Yu, D., Li, Y., Ming, Z., Wang, H., Dong, Z., Qiu, L., & Wang, T. (2018). Comprehensive circular RNA expression profile in radiation-treated HeLa cells and analysis of radioreistance-related circRNAs. Peer Journal, 6, e5011.

Zhang, M., & Xin, Y. (2018). Circular RNAs: A new frontier for cancer diagnosis and therapy. Journal of Hematology & Oncology, 11(1), 21.

How to cite this article: Jiao J, Zhang T, Jiao X, et al. hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration and invasion. J Cell Physiol. 2020;235:1287–1295. https://doi.org/10.1002/jcp.29045